Abstract
On December 29, 1993, the Food And Drug Administration approved the new antipsychotic agent risperidone (Risperdal) for use in the United States. Risperidone is the first of a new class of antipsychotic agents known as serotonin/dopamine antagonists. It is only the second new antipsychotic medication to be introduced in this country during the past two decades. Early efficacy studies show that risperidone has marked superiority in reducing both positive and negative symptoms over placebos and haloperidol. Risperidone does not produce the blood dyscrasias associated with clozapine and possesses a relatively dean adverse reaction profile. Maximum therapeutic responses have been observed with doses of 4 mg to 8 mg; higher dosages have resulted in extrapyramidal symptoms without added benefits.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Psychosocial Nursing and Mental Health Services
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
